# UNITED STATES SECURITIES EXCHANGE COMMISSION Washington, D.C. 20549


SCHEDULE 13G (Amendment No. 2)

**Under the Securities Exchange Act of 1934** 

Oramed Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, \$0.001 par value (Title of Class of Securities)

68403P104 (CUSIP Number)

August 28, 2012
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X ] Rule 13d-1(c)

[ ] Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages Page 1 of 10 Pages Exhibit Index: Page 9

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1	NAME OF REPORT	NAME OF REPORTING PERSONS				
	I.R.S. IDENTIFICA	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Regals Capital Mana	agement	LP			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
	(a) [] (b) []					
3	SEC USE ONLY					
3						
4	CITIZENSHIP OR	PLACE	OF ORGANIZATION			
	Delaware					
NUM	BER OF	5	SOLE VOTING POWER			
SH	ARES		None			
BENEI	FICIALLY	6	SHARED VOTING POWER			
OWI	NED BY		13,029,698			
E	ACH	7	SOLE DISPOSITIVE POWER			
REPO	ORTING		None			
PE	RSON	8	SHARED DISPOSITIVE POWER			
W	VITH		13,029,698			
9	AGGREGATE AMO	OUNT E	BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	13,029,698					
10			GREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]			
10	CILCREDATE THE MODILE MINOCITE IN NOW (3) ENCEODES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT OF CLA	SS REP	PRESENTED BY AMOUNT IN ROW (9)			
	15.4%					
12	TYPE OF REPORT	ING PE	RSON (See Instructions)			
	PN					

1	NAME OF REPOR	NAME OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Regals Fund LP				
2	CHECK THE APP	ROPRIA	TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
_	(a) [] (b) []				
3	SEC USE ONLY		(3)		
3	SEC USE OIVET				
4	CITIZENSHIP OR PLACE OF ORGANIZATION		OF ORGANIZATION		
	Delaware				
NUM	IBER OF	5	SOLE VOTING POWER		
SH	IARES		None		
BENEI	FICIALLY	6	SHARED VOTING POWER		
	NED BY	Ū	13,029,698		
	ACH		SOLE DISPOSITIVE POWER		
	ORTING	7			
	ERSON		None		
		8	SHARED DISPOSITIVE POWER		
V	VITH		13,029,698		
9	AGGREGATE AM	OUNT E	BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	13,029,698	3			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]				
11		ASS REF	PRESENTED BY AMOUNT IN ROW (9)		
	15.4%	15.4%			
12	TYPE OF REPORT	ING PE	RSON (See Instructions)		
	PN				

1	NAME OF REP	NAME OF REPORTING PERSONS				
	I.R.S. IDENTIFI	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	David M. Slager					
<u> </u>			TE DOV IT A MEMBER OF A CROUD (SEE INCEDITIONS)			
2	CHECK THE AI	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) [ ]				
			(b) [ ]			
3	SEC USE ONLY	SEC USE ONLY				
4	CITIZENSHIP C	ITIZENSHIP OR PLACE OF ORGANIZATION				
	Dutch					
NUM	IBER OF	5	SOLE VOTING POWER			
SH	HARES		None			
BENE	FICIALLY	6	SHARED VOTING POWER			
OW	NED BY	ŭ	13,029,698			
	EACH					
		7	SOLE DISPOSITIVE POWER			
REP	ORTING		None			
PE	ERSON	8	SHARED DISPOSITIVE POWER			
V	WITH		13,029,698			
9	AGGREGATE A	MOUNT B	EENEFICIALLY OWNED BY EACH REPORTING PERSON			
-						
		13,029,698				
10	CHECK BOX IF	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]				
11	PERCENT OF C	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11						
		15.4%				
12	TYPE OF REPO	"YPE OF REPORTING PERSON (See Instructions)				
	IN					

This Amendment No. 2 is filed with respect to the shares of Common Stock (as defined below) of Oramed Pharmaceuticals, Inc., beneficially owned by the Reporting Persons (as defined below) and amends and restates the initial Schedule 13G filed by the Reporting Persons on April 13, 2012.

# Item 1(a). Name of Issuer:

Oramed Pharmaceuticals, Inc. (the "Issuer").

# Item 1(b). Address of Issuer's Principal Executive Offices:

Hi-Tech Park 2/5 Givat-Ram PO Box 39098 Jerusalem 91390 Israel

# Item 2(a). Name of Person Filing

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i) Regals Capital Management LP ("Regals Management"), which serves as investment manager to Regals Fund LP ("Regals Fund") with respect to the shares of Common Stock (as defined in Item 2(d) below) directly owned by Regals Fund;
- ii) Regals Fund; and
- iii) David M. Slager ("Mr. Slager")

# Item 2(b). Address of Principal Business Office or, if None, Residence

The address of the principal business office of each of Regals Management, Regals Fund and Mr. Slager is 152 West 57th Street, 9th Floor, New York, New York 10019.

# Item 2(c). Citizenship

- i) Regals Management is a Delaware limited partnership;
- ii) Regals Fund is a Delaware limited partnership; and
- iii) Mr. Slager is a citizen of the Netherlands.

# Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share (the "Common Stock")

# Item 2(e). CUSIP Number:

68403P104

# Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

This Item 3 is not applicable.

#### Item 4. Ownership:

# Item 4(a) Amount Beneficially Owned:

See Item 9 of the attached cover page.

# Item 4(b) Percent of Class:

See Item 11 of the attached cover page.

# Item 4(c) Number of Shares of which such person has:

(i) Sole power to vote or direct the vote:

See Item 5 of the attached cover page.

(ii) Shared power to vote or direct the vote:

See Item 6 of the attached cover page.

(iii) Sole power to dispose or direct the disposition of:

See Item 7 of the attached cover page.

(iv) Shared power to dispose or direct the disposition of:

See Item 8 of the attached cover page.

Regals Management is the investment manager of Regals Fund, the holder of the Common Stock reported herein. Mr. Slager is the managing member of the general partner of Regals Management. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of the Common Stock reported herein, as well as the power to dispose or direct the disposition of the Common Stock reported herein is held by Mr. Slager through Regals Management.

The 13,029,698 shares of Common Stock beneficially owned by the Reporting Persons consist of: (a) 8,722,265 shares of Common Stock, and (b) warrants exercisable for 4,307,433 shares of Common Stock.

# Item 5. Ownership of Five Percent or Less of a Class:

This Item 5 is not applicable.

# Item 6. Ownership of More than Five Percent on Behalf of Another Person:

This Item 6 is not applicable.

# Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

This Item 7 is not applicable.

# Item 8. Identification and Classification of Members of the Group:

This Item 8 is not applicable.

# Item 9. Notice of Dissolution of Group:

This Item 9 is not applicable.

#### Item 10. Certification:

By signing below each of the Reporting Persons certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of their knowledge and belief, each of the Reporting Persons certifies that the information set forth in this statement is true, complete and correct.

Date: September 6, 2012 REGALS CAPITAL MANAGEMENT LP

By: Regals Capital Holdings LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

September 6, 2012 REGALS FUND LP

By: Regals Fund GP LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

Date: September 6, 2012 DAVID M. SLAGER

Date:

By: <u>/s/ David M. Slager</u> Name: David M. Slager

# EXHIBIT INDEX

Ex. Page No.

A. Joint Filing Agreement, dated as of September 6, 2012 by and among Regals Capital Management LP, Regals Fund LP and David Slager

10

#### **EXHIBIT A**

# JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, par value \$0.001 per share, of Oramed Pharmaceuticals, Inc., dated as of September 6, 2012 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: September 6, 2012 REGALS CAPITAL MANAGEMENT LP

Date:

Date:

September 6, 2012

September 6, 2012

By: Regals Capital Holdings LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

REGALS FUND LP

By: Regals Fund GP LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

DAVID M. SLAGER

By: <u>/s/ David M. Slager</u> Name: David M. Slager